In the ARISTOTLE trial, apixaban had a greater reduction of hemorrhagic stroke compared to the warfarin group (HR 0.51; 95% CI 0.35 to 0.75; p less than 0.001). For the secondary outcome of death from any cause, apixaban was superior to warfarin (HR 0.89; 95% CL 0.8 to 0.998; p=0.047).